Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19054630 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19027181 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | January 2025 | November 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 19023934 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | January 2025 | March 2026 | Allow | 14 | 1 | 0 | Yes | No |
| 19007236 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19002832 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | December 2024 | October 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18970575 | BASE EDITOR AND THE USE THEREOF | December 2024 | December 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18932745 | COMPOSITIONS FOR INDUCING MODIFICATIONS OF TARGET ENDOGENOUS NUCLEIC ACID SEQUENCES IN NUCLEUSES OF EUKARYOTIC CELLS | October 2024 | August 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 18820460 | CRISPR-CAS SYSTEMS AND USES THEREOF | August 2024 | July 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18755750 | CRISPR-CAS13 SYSTEM AND USE THEREOF | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18607210 | GUIDED MICROBIAL REMODELING, A PLATFORM FOR THE RATIONAL IMPROVEMENT OF MICROBIAL SPECIES FOR AGRICULTURE | March 2024 | November 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18408504 | Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction | January 2024 | January 2026 | Abandon | 25 | 1 | 0 | No | No |
| 18406053 | COMBINATORIAL TARGETED THERAPY METHODS | January 2024 | February 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18543827 | MODIFIED NUCLEIC ACIDS, HYBRID GUIDE RNAS, AND USES THEREOF | December 2023 | February 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18537662 | Allosteric Conditional Guide RNAs for Cell-Selective Regulation of CRISPR/Cas | December 2023 | April 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18520878 | SYSTEMS AND METHODS FOR TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF USING INTEGRATED PRIMING SITES | November 2023 | March 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18488109 | MODULAR DNA-BINDING DOMAINS AND METHODS OF USE | October 2023 | October 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18374673 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | September 2023 | October 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18477291 | COMPOSITIONS FOR GENOME EDITING | September 2023 | December 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18552549 | AAV-IDS VECTORS FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS II | September 2023 | March 2026 | Allow | 29 | 0 | 0 | Yes | No |
| 18467297 | METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN THE SAME | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18467356 | METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN THE SAME | September 2023 | October 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18460058 | gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING | September 2023 | October 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18452508 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | August 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18219524 | BIOCONTAINMENT/BIOCONTROL SYSTEM AND METHODS | July 2023 | May 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18345653 | GENE EDITING | June 2023 | June 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18334046 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | June 2023 | December 2025 | Allow | 30 | 4 | 0 | Yes | No |
| 18332029 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | June 2023 | October 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18127853 | CRISPR-CAS BASED SYSTEM FOR TARGETING SINGLE-STRANDED SEQUENCES | March 2023 | August 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18114112 | ADMINISTRATION REGIME | February 2023 | July 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18166746 | A HTP PLATFORM FOR THE GENETIC ENGINEERING OF CHINESE HAMSTER OVARY CELLS | February 2023 | June 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18104640 | METHODS AND KITS FOR IDENTIFYING CANCER TREATMENT TARGETS | February 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18068061 | DNA EDITING USING SINGLE-STRANDED DNA | December 2022 | September 2025 | Abandon | 33 | 2 | 1 | No | No |
| 18064011 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA DIRECTED MODULATION OF TRANSCRIPTION | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17999341 | HDR ENHANCERS | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17926208 | USE OF A DEFICIENT FUSION PROTEIN FOR NUCLEASE ACTIVITY SO AS TO INDUCE MEIOTIC RECOMBINATIONS | November 2022 | February 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 18054538 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17911646 | FNCPF1 MUTANT FOR BROAD-SPECTRUM IDENTIFICATION ON PAM SEQUENCE ANS USE THEREOF | September 2022 | November 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17931018 | RNA GUIDED COMPOSITIONS FOR PREVENTING AND TREATING HEPATITIS B VIRUS INFECTIONS | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17930079 | In Vitro Cleavage of DNA Using Argonaute | September 2022 | July 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17823076 | MIR-149-3P AND METHOD FOR TREATING METABOLIC DISEASE USING THE SAME | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17794263 | CONSTRUCTION OF HIGH-FIDELITY CRISPR/ASCPF1 MUTANT AND USES THEREOF | July 2022 | December 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17757289 | LONG NON-CODING RNA LETN SERVING AS TUMOR MARKER AND THERAPEUTIC TARGET POINT | June 2022 | December 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17750116 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | May 2022 | April 2025 | Abandon | 35 | 4 | 0 | Yes | Yes |
| 17749017 | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF | May 2022 | November 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17744475 | COMPOSITIONS AND METHODS OF TREATMENT FOR LYTIC AND LYSOGENIC VIRUSES | May 2022 | May 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17775490 | SELECTION MARKER FREE METHODS FOR MODIFYING THE GENOME OF BACILLUS AND COMPOSITIONS THEREOF | May 2022 | November 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17770512 | LIGHT-INDUCIBLE CRISPR/CAS9 SYSTEM FOR GENOME EDITING | April 2022 | November 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17762591 | A PROMOTER SPECIFIC FOR NON-PIGMENTED CILIARY EPITHELIAL CELLS | March 2022 | October 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17639043 | MODIFIED BACTERIAL RETROELEMENT WITH ENHANCED DNA PRODUCTION | February 2022 | January 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17588289 | YAP1 Gene-Modified Mesenchymal Stem Cell and Preparation Method Thereof | January 2022 | December 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17559860 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | December 2021 | November 2024 | Allow | 34 | 1 | 0 | No | No |
| 17514919 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | August 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17514936 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | November 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17514929 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | October 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17514893 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17514908 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17514883 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17514940 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | October 2021 | November 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17436208 | HIGH-THROUGHPUT GENE-EDITING TECHNIQUE | October 2021 | December 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17605214 | TAILORED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORS | October 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17604119 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17481056 | TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE | September 2021 | September 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17593556 | GENETIC RISK ANALYSIS FOR POST-TRAUMATIC STRESS DISORDERS AND BEHAVIORAL MANAGEMENT THEREOF | September 2021 | November 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17436510 | ENHANCED HUMAN OPSIN PROMOTER FOR ROD SPECIFIC EXPRESSION | September 2021 | December 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17433927 | COMPOSITIONS AND METHODS FOR TREATING LAMINOPATHIES | August 2021 | April 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17407928 | COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS | August 2021 | December 2025 | Allow | 51 | 5 | 0 | Yes | No |
| 17430665 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | August 2021 | November 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17430298 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | August 2021 | July 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17427410 | NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS | July 2021 | August 2025 | Allow | 49 | 2 | 0 | No | No |
| 17388321 | TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS | July 2021 | February 2025 | Allow | 42 | 2 | 0 | No | No |
| 17425876 | MITOCHONDRIAL GENOME EDITING METHODS | July 2021 | July 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17348619 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17348596 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION | June 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17294175 | CRISPR/CAS12J ENZYME AND SYSTEM | May 2021 | June 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17246081 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | April 2021 | February 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17284660 | METHODS AND KITS FOR IDENTIFYING CANCER TREATMENT TARGETS | April 2021 | February 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17269958 | BIOMARKER FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) | February 2021 | February 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17262782 | BIOSENSORS FOR DETECTING ARRESTIN SIGNALING | January 2021 | August 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17054938 | MIRI26-5P FOR TREATING MOTOR NEURON DISEASES | November 2020 | March 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16999649 | CLEAVAGE-RESISTANT DONOR NUCLEIC ACIDS AND METHODS OF USE | August 2020 | November 2024 | Abandon | 51 | 4 | 1 | No | No |
| 16992815 | EXTRACHROMOSOMAL DNA LABELING | August 2020 | December 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16913299 | RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS | June 2020 | February 2025 | Allow | 55 | 1 | 0 | Yes | No |
| 16865129 | COMPOSITIONS AND METHODS FOR GENERATING DIVERSITY AT TARGETED NUCLEIC ACID SEQUENCES | May 2020 | March 2025 | Abandon | 59 | 6 | 1 | Yes | No |
| 16644445 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | March 2020 | February 2025 | Abandon | 59 | 2 | 1 | No | No |
| 16698276 | METHODS AND COMPOSITIONS FOR MODIFYING A SINGLE STRANDED TARGET NUCLEIC ACID | November 2019 | December 2024 | Abandon | 60 | 3 | 0 | Yes | No |
| 16463883 | GENOME EDITING METHOD | October 2019 | January 2025 | Abandon | 60 | 6 | 0 | No | No |
| 16603377 | Compounds for Increasing Genome Editing Efficiency | October 2019 | August 2024 | Allow | 58 | 4 | 1 | Yes | No |
| 16499889 | Method of Recording Multiplexed Biological Information into a CRISPR Array Using a Retron | October 2019 | August 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16486799 | GENE EDITING THERAPY FOR HIV INFECTION VIA DUAL TARGETING OF HIV GENOME AND CCR5 | August 2019 | April 2025 | Abandon | 60 | 4 | 2 | No | Yes |
| 16482294 | Methods for Increasing Efficiency of Gene Editing in Cells | July 2019 | April 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16469098 | COMPOSITIONS AND METHODS FOR CRISPR-BASED SCREENING | June 2019 | March 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16417499 | Methods for mitochondria and organelle genome editing | May 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16343987 | MODULAR EXTRACELLULAR SENSOR ARCHITECTURE FOR REGULATING GENES | April 2019 | May 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16341025 | NANOPARTICLES FUNCTIONALIZED WITH GENE EDITING TOOLS AND RELATED METHODS | April 2019 | November 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16326908 | SINGLE GUIDE RNA/CRISPR/CAS9 SYSTEMS, AND METHODS OF USE THEREOF | February 2019 | November 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16100040 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES | August 2018 | January 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16040204 | METHYLENE-TETRAHYDROFOLATE REDUCTASE ISOFORM-BASED BIOMARKER AND METHOD OF USE THEREOF | July 2018 | September 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 15769180 | EXPRESSION IN MAMMALIAN CELLS WITH GAUSSIA LUCIFERASE SIGNAL PEPTIDE | April 2018 | August 2024 | Allow | 60 | 8 | 1 | Yes | No |
| 15335139 | NUCLEIC ACID ENRICHMENT USING CAS9 | October 2016 | May 2025 | Abandon | 60 | 9 | 1 | No | Yes |
| 14897213 | ANALYSIS OF POLYNUCLEOTIDES | December 2015 | June 2025 | Allow | 60 | 10 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KONOPKA, CATHERINE ANNE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KONOPKA, CATHERINE ANNE works in Art Unit 1635 and has examined 50 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner KONOPKA, CATHERINE ANNE's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KONOPKA, CATHERINE ANNE receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KONOPKA, CATHERINE ANNE is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +76.5% benefit to allowance rate for applications examined by KONOPKA, CATHERINE ANNE. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.0% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.0% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.